IP Library Granted Patent US 9,745,316
Granted Patent B2
US 9,745,316 · App. 14/982,443 · Granted Aug 29, 2017

Lactam kinase inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,745,316
App. No.
14/982,443
Granted
Aug 29, 2017
Kind
B2
Abstract

Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.

Claims (34)

1. A compound of formula (QQ):

wherein

R 26 is H or C 1 -C 6 alkyl;

R 27 is -(alkylene) m -C 3 -C 8 cycloalkyl or -(alkylene) m -aryl; any of which may be optionally independently substituted with one or more R x groups as allowed by valance;

each R 31 is alkyl or two R 31 s on adjacent ring atoms or on the same ring atom together with the ring atom(s) to which they are attached optionally form a 3-8-membered cycle;

yy is 0, 1, 2, 3, or 4;

ZZ is —(CH 2 ) xx —, wherein xx is 1 or 2;

R 77 is -(alkylene) m -heterocyclo or —(alkylene) m -NR 3 R 4 , any of which may be optionally independently substituted with one or more R x groups as allowed by valance;

R 3 and R 4 at each occurrence are independently selected from:

(i) hydrogen, or

(ii) alkyl, heterocyclo, or heteroaryl;

R x at each occurrence is independently selected from halo, cyano, nitro, oxo, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkyl, and

m is 0 or 1.

2. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein R 26 is selected from the group consisting of H, methyl, ethyl, n-propyl, and sec-butyl.

5. The compound of claim 1 , wherein R 31 is selected from the group consisting of methyl, ethyl, n-propyl, and iso-propyl.

6. The compound of claim 1 , wherein R 27 is selected from the group consisting of phenyl, ortho-methylphenyl, ortho, ortho-dimethylphenyl, para-ethylphenyl and ortho, para-dichlorophenyl.

7. The compound of claim 1 , wherein yy is 0, 1 or 2.

8. The compound of claim 1 , wherein R 3 and R 4 are independently selected from the group consisting of H, methyl, and ethyl.

9. The compound of claim 1 , wherein R x is selected from the group consisting of chloro, methyl, ethyl, and cyclopentyl.

10. The compound of claim 1 , wherein R 77 is selected from the group consisting of 1-morpholino, 2-methyl-1-morpholino, and 2,6-dimethyl-1-morpholino.

11. A pharmaceutical composition comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. The compound of claim 1 , wherein R 27 is C 3 -C 8 cycloalkyl or phenyl.

13. The compound of claim 12 , wherein R 77 is heterocyclo.

14. The compound of claim 13 , wherein heterocyclo is piperazine.

15. The compound of claim 12 , wherein m is 0 and R 77 is heterocyclo substituted with one R x group.

16. The compound of claim 15 , wherein heterocyclo is piperazine and R x is alkyl.

17. The compound of claim 16 , wherein yy is 2 and xx is 2.

18. The compound of claim 17 , wherein two R 31 s on the same ring atom together with the ring atom to which they are attached form a 3-8-membered cycle.

19. The compound of claim 18 , wherein the 3-8-membered cycle is a 6 membered cycle.

20. The compound of claim 19 , wherein R 26 is H.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2024
From: G1 THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 069501/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2024
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 069501/0824 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 19, 2024
From: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
To: G1 THERAPEUTICS, INC.
Reel/Frame 068996/0001 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 29, 2020
From: G1 THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
Reel/Frame 052795/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2016
From: TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 039241/0450 →